Goal is to be the First With Regenerative Therapy Aimed At Recovery of Function After Stroke
Updated 10:01 AM ET May 26, 2000
Current quotes (delayed 20 mins.) BLSI 8 1/16 11/16 (9.32%)
BOSTON (BW HealthWire) - Boston Life Sciences, Inc. (NASDAQ:BLSI) announced that the Company has initiated a program to develop its CNS nerve regenerative factor Inosine as therapy to enhance functional recovery following stroke. Development of Inosine for this indication is in addition to its ongoing development for functional recovery in spinal cord injury. "The use of Inosine to regenerate nerve connections in stroke represents a totally new approach to this devastating condition," stated Dr. Marc Lanser, Chief Scientific Officer of BLSI. "In simple terms, stroke is essentially caused by an acute blockage of a blood vessel to a specific area of the brain. Depending on the extent of the territory vascularized by this vessel, clinical consequences range from minor debility to death. As far as we are aware, all current therapies, both approved or in development, are focused on minimizing the damage to the affected territory of the brain, either by reversing the blockage (by clot dissolution) or protecting brain cells from the ischemic injury (cytoprotective agents). However, once the damage is complete, there is little or no functional recovery, since there is little or no nerve regeneration in the CNS that could compensate for the irreversible loss of the nerve cells and their connections. Up to now, the inability to provide regeneration therapy for stroke has been simply due to the absence of any effective compounds having the necessary in vivo regenerative activity."
"Inosine, the Company's lead compound for nerve regeneration, easily appears to be the most effective compound ever identified (as documented in the scientific literature) in regenerating nerve connections in the CNS. Based on our previous results in stimulating nerve regeneration in the long motor tracts of the spinal cord (as published in the November 9, 1999 issue of the Proceedings of the National Academy of Sciences), we are very excited at the prospect that Inosine may eventually prove to be an effective regenerative therapy for stroke," added Dr. Lanser.
Inosine can be conveniently administered directly into the Cerebral Spinal Fluid (CSF) which bathes the brain, thereby exposing the specifically injured brain tissue to therapeutic amounts of Inosine while minimizing the potential for systemic toxicity. Inosine can potentially be administered via a widely-used delivery system for several months if necessary, in order to promote the optimal amount of regeneration. The Company's Inosine Development Program will concentrate on the optimization of dosage and duration of treatment, pharmacokinetic and toxicity studies, and cGMP production of Inosine for human use. If the preclinical development program is successful, the Company hopes to initiate human trials in 2001.
BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease (PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments for cancer, autoimmune disease, and central nervous system disorders. BLSI's products in development include: Altropane, a radioimaging agent for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; fusion toxins for the treatment of cancer and multiple sclerosis; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies.
Statements made in this press release other than statements of historical fact represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, discussions with regulatory agencies, schedules of IND, NDA and all other regulatory submissions, the timing of product introductions, the possible approval of products, and the market size and possible advantages of the Company's products. All such forward-looking statements involve substantial risks and uncertainties, and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, the ability to obtain intellectual property protection, delays in the regulatory or development processes, results of scientific data from clinical trials, the outcome of discussions with potential partners, regulatory decisions, market acceptance of the Company's products, and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K.
Contact: Investors Boston Life Sciences, Inc. Maria Zapf 617.425.0200,
ext.17 www.bostonlifesciences.com or The Trout Group Brandon Lewis 212.477.9007,
ext. 15 www.troutgroup.com or Corporate Boston Life Sciences, Inc. Marc
Lanser, MD Chief Scientific Officer 617.425.0200 or Media Schwartz Communications
Jim Weinrebe 781.684.0770 www.schwartz-pr.com